Tumor cells (viral oncolysis) + IL-12 immune activation

Class

Oncolytic adenovirus (serotype 5), IL-12-armed

Pathway

Viral-mediated tumor cell lysis plus non-secreting IL-12 payload driving cytotoxic T-lymphocyte antitumor immune response

This mechanism combines two anticancer strategies delivered by a single, engineered adenovirus. The virus is designed to replicate selectively within tumor cells, exploiting the fact that cancer cells often carry defects in growth-regulatory and antiviral pathways that permit unchecked viral replication, while normal cells restrict it. As the virus multiplies, it ruptures (lyses) infected tumor cells directly, an effect called oncolysis, and this process releases tumor antigens and danger signals that can alert the immune system. The virus is additionally engineered to produce interleukin-12 (IL-12), a cytokine that stimulates cytotoxic T lymphocytes and natural killer cells, amplifying an antitumor immune response beyond the site of direct viral killing. The rationale for pairing oncolysis with local IL-12 production is that many solid tumors evade immune attack by maintaining a poorly inflamed ('cold') microenvironment; combining direct tumor destruction with a potent immune-activating signal aims to convert that environment into one that supports sustained, cytotoxic T-cell-mediated tumor control. This class of therapy is of broad interest across solid tumors that are resistant to standard immunotherapy, particularly where limited immune infiltration is a barrier to durable responses.